A. Earle Weeks, MD, is a Medical Oncologist and Hematologist at West Cancer Center.
Titles and Roles
- Medical Oncologist and Hematologist, West Cancer Center
Areas of Expertise
- Medical Oncology
Dr. Weeks has recently joined West Cancer Center’s Department of Medical Oncology and Hematology from Integrity Oncology, where he was co-founder and served as a Medical Oncologist and Hematologist. Dr. Weeks came to Memphis from U.T. Medical School at Houston and completed Fellowships in Hematology and Oncology from the Department of Medical Oncology University of Texas M.D. Anderson Cancer Center, Houston. He was also an Instructor in Medicine and Oncology at U.T. Medical School at Houston. Once in Memphis, he was on the Clinical Faculty in the Department of Medicine, University of Tennessee Health Science Center, and served as Chief of Medicine at St. Francis Hospital. He is dedicated to serving patients in a manner that not only focuses on providing the most innovative and effective treatment, but also the most compassionate and supportive. He is a member of several professional organizations, including the American College of Physicians, American Medical Association, Memphis and Shelby County Medical Society, and MD Anderson Associates.
Dr. Weeks is married to a Pediatric Oncologist at St. Jude Children’s Research Hospital and they have two daughters. He enjoys active outdoor activities. In 2011, he accomplished his goal of running a marathon in every state in the nation and will complete the second time around in 2017.
Education and Training
Dr. Weeks earned his M.D. from the University of Texas Medical School at Houston in 1983. At the University of Texas Affiliated Hospitals, he completed his clinical internship in 1984 and clinical residency in 1986. He then went on to complete his fellowship at the University of Texas MD Anderson Cancer Center in 1988.
Dr. Weeks’ most significant research projects include:
- Phase I study of combination therapies for patients with Metastatic Carcinoma
- Phase I Clinical and Pharmacologic study of Difluorodeoxycytidine